Saied Ghadersohi1, Caroline P E Price1, Sally E Jensen2, Jennifer L Beaumont3, Robert C Kern4, David B Conley1, Kevin C Welch1, Anju T Peters5, Leslie C Grammer5, Whitney W Stevens4, Alexis M Calice1, Elizabeth Stanton1, Marisa K VanderMeeden1, Robert P Schleimer4, Bruce K Tan6. 1. Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 2. Department of Medical Social Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 3. Terasaki Research Institute, Los Angeles, Calif. 4. Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Division of Allergy and Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 5. Division of Allergy and Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 6. Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Division of Allergy and Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Ill. Electronic address: b-tan@northwestern.edu.
Abstract
BACKGROUND: Patient-reported outcome (PRO) measures developed and validated on patients with the currently defined phenotypes of chronic rhinosinusitis (CRS) are needed to support clinical trials in CRS. OBJECTIVE: This study developed and examined the initial reliability and validity of the CRS-PRO, a new PRO measure of CRS. METHODS: Instrument development was performed through structured interviews and focus groups with clinical experts and 45 patients with CRS meeting current definitions of disease, 21 patients with CRS without nasal polyps (CRSsNP), and 24 patients with CRS with nasal polyps (CRSwNP) to identify items important to patients. Then another 50 patients (32 with CRSsNP and 18 with CRSwNP) with stable CRS symptoms were enrolled to evaluate the reliability of the instrument. Each patient completed the CRS-PRO, Sinonasal Outcome Test-22 (SNOT-22), and 4 Patient-Reported Outcome Measurement Information System short forms at the baseline visit and then at least 7 days later. RESULTS: After the development process, 21 items were identified from the conceptual domains of physical symptoms, sensory impairment, psychosocial effects, and life impact. Using the responses of the 50 patients with CRS, 21 draft items were further refined to 12 items by eliminating conceptually similar or highly correlated items or those with low mean symptom severity. The 12-item questionnaire was shown to have excellent internal consistency (Cronbach α, 0.86) and test-retest reliability with a high intraclass correlation coefficient (0.89) and Pearson's correlation (r = 0.82, P < .0001). The 12-item CRS-PRO correlated highly with the longer SNOT-22 (r = 0.83, P < .0001) demonstrating its concurrent validity. We also demonstrated validity and reliability in a separate analysis for patients with CRSsNP and CRSwNP. CONCLUSION: The CRS-PRO is a concise, valid, and reliable measure that was developed with extensive input from patients with CRS with current disease definitions.
BACKGROUND: Patient-reported outcome (PRO) measures developed and validated on patients with the currently defined phenotypes of chronic rhinosinusitis (CRS) are needed to support clinical trials in CRS. OBJECTIVE: This study developed and examined the initial reliability and validity of the CRS-PRO, a new PRO measure of CRS. METHODS: Instrument development was performed through structured interviews and focus groups with clinical experts and 45 patients with CRS meeting current definitions of disease, 21 patients with CRS without nasal polyps (CRSsNP), and 24 patients with CRS with nasal polyps (CRSwNP) to identify items important to patients. Then another 50 patients (32 with CRSsNP and 18 with CRSwNP) with stable CRS symptoms were enrolled to evaluate the reliability of the instrument. Each patient completed the CRS-PRO, Sinonasal Outcome Test-22 (SNOT-22), and 4 Patient-Reported Outcome Measurement Information System short forms at the baseline visit and then at least 7 days later. RESULTS: After the development process, 21 items were identified from the conceptual domains of physical symptoms, sensory impairment, psychosocial effects, and life impact. Using the responses of the 50 patients with CRS, 21 draft items were further refined to 12 items by eliminating conceptually similar or highly correlated items or those with low mean symptom severity. The 12-item questionnaire was shown to have excellent internal consistency (Cronbach α, 0.86) and test-retest reliability with a high intraclass correlation coefficient (0.89) and Pearson's correlation (r = 0.82, P < .0001). The 12-item CRS-PRO correlated highly with the longer SNOT-22 (r = 0.83, P < .0001) demonstrating its concurrent validity. We also demonstrated validity and reliability in a separate analysis for patients with CRSsNP and CRSwNP. CONCLUSION: The CRS-PRO is a concise, valid, and reliable measure that was developed with extensive input from patients with CRS with current disease definitions.
Authors: Richard R Orlandi; Todd T Kingdom; Peter H Hwang; Timothy L Smith; Jeremiah A Alt; Fuad M Baroody; Pete S Batra; Manuel Bernal-Sprekelsen; Neil Bhattacharyya; Rakesh K Chandra; Alexander Chiu; Martin J Citardi; Noam A Cohen; John DelGaudio; Martin Desrosiers; Hun-Jong Dhong; Richard Douglas; Berrylin Ferguson; Wytske J Fokkens; Christos Georgalas; Andrew Goldberg; Jan Gosepath; Daniel L Hamilos; Joseph K Han; Richard Harvey; Peter Hellings; Claire Hopkins; Roger Jankowski; Amin R Javer; Robert Kern; Stilianos Kountakis; Marek L Kowalski; Andrew Lane; Donald C Lanza; Richard Lebowitz; Heung-Man Lee; Sandra Y Lin; Valerie Lund; Amber Luong; Wolf Mann; Bradley F Marple; Kevin C McMains; Ralph Metson; Robert Naclerio; Jayakar V Nayak; Nobuyoshi Otori; James N Palmer; Sanjay R Parikh; Desiderio Passali; Anju Peters; Jay Piccirillo; David M Poetker; Alkis J Psaltis; Hassan H Ramadan; Vijay R Ramakrishnan; Herbert Riechelmann; Hwan-Jung Roh; Luke Rudmik; Raymond Sacks; Rodney J Schlosser; Brent A Senior; Raj Sindwani; James A Stankiewicz; Michael Stewart; Bruce K Tan; Elina Toskala; Richard Voegels; De Yun Wang; Erik K Weitzel; Sarah Wise; Bradford A Woodworth; Peter-John Wormald; Erin D Wright; Bing Zhou; David W Kennedy Journal: Int Forum Allergy Rhinol Date: 2016-02 Impact factor: 3.858
Authors: Sarfaraz M Banglawala; Rodney J Schlosser; Kristen Morella; Rakesh Chandra; Justin Khetani; David M Poetker; Meera Rayar; Luke Rudmik; Nathan B Sautter; Doron D Sommer; Timothy L Smith; Zachary M Soler Journal: Int Forum Allergy Rhinol Date: 2015-12-18 Impact factor: 3.858
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinology Date: 2012-03 Impact factor: 3.681
Authors: Karon F Cook; Sally E Jensen; Benjamin D Schalet; Jennifer L Beaumont; Dagmar Amtmann; Susan Czajkowski; Darren A Dewalt; James F Fries; Paul A Pilkonis; Bryce B Reeve; Arthur A Stone; Kevin P Weinfurt; David Cella Journal: J Clin Epidemiol Date: 2016-03-04 Impact factor: 6.437
Authors: Junqin Bai; Julia H Huang; Caroline P E Price; Jacob M Schauer; Lydia A Suh; Regan Harmon; David B Conley; Kevin C Welch; Robert C Kern; Stephanie Shintani-Smith; Anju T Peters; Whitney W Stevens; Atsushi Kato; Robert P Schleimer; Bruce K Tan Journal: J Allergy Clin Immunol Date: 2022-03-16 Impact factor: 14.290
Authors: Samuel D Racette; Alexander L Schneider; Meera Ganesh; Julia H Huang; David S Lehmann; Caroline P E Price; Samuel G Rodegherio; Abhita T Reddy; Jacob G Eide; David B Conley; Kevin C Welch; Robert C Kern; Stephanie Shintani-Smith; Atsushi Kato; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2022-04-01 Impact factor: 5.426
Authors: Alexander L Schneider; Samuel D Racette; Anthony K Kang; Abhita T Reddy; Julia H Huang; David S Lehmann; Caroline P E Price; Jacob G Eide; Samuel R Rodeghiero; David B Conley; Kevin C Welch; Robert C Kern; Stephanie Shintani-Smith; Anju T Peters; Atsushi Kato; Whitney S Stevens; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2022-04-01 Impact factor: 5.426
Authors: Katherine A Lin; Caroline P E Price; Julia H Huang; Saied Ghadersohi; David Cella; Robert C Kern; David B Conley; Stephanie Shintani-Smith; Kevin C Welch; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2021-03-16 Impact factor: 5.426